WX-UK1

WX-UK1 is a 3-amidinophenylalanine-based non-cytotoxic small molecule inhibitor developed primarily by Wilex (now Heidelberg Pharma AG) as an antineoplastic agent. It acts by inhibiting serine proteases—specifically the urokinase-type plasminogen activator (uPA) system and related trypsin-like enzymes—which are implicated in tumor cell invasion, metastasis formation, and primary tumor growth. Preclinical studies demonstrated that WX-UK1 can reduce both metastasis and primary tumor size in animal models of breast cancer and other solid tumors. The drug was investigated for use in various solid tumors including gastric, ovarian, pancreatic cancers and participated in phase I clinical trials (often combined with capecitabine or gemcitabine). Clinical development was discontinued after early-phase trials[1][2][3][4][5].

Other names

WX-UK1WX-UK-1WX-UK 1WX UK1WXUK1WXUK-1WXUK 1